Bioprocess Bags Market By Type (Single-Use Bioprocess Bags, Multi-Layer Bioprocess Bags, Bioprocess Bag Assemblies), By Application (Cell Culture, Biopharmaceutical Production, Drug Discovery & Development, Protein Purification, Vaccine Production), By End-Use Industry (Pharmaceuticals & Biotechnology, Healthcare, Food & Beverages, Chemical & Cosmetics), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Bioprocess Bags Market was valued at USD 3.1 billion in 2024-e and will surpass USD 5.7 billion by 2030; growing at a CAGR of 10.4% during 2025 - 2030.

The bioprocess bags market is experiencing rapid growth, driven by the increasing demand for single-use technologies in the biopharmaceutical and biotechnology industries. Bioprocess bags, essential for cell culture, biopharmaceutical production, and other critical processes, offer significant advantages over traditional stainless-steel equipment. They reduce the risk of contamination, improve flexibility, and lower operational costs, which makes them highly attractive for biopharmaceutical companies looking to streamline manufacturing and production processes.

With the growing focus on biologics, vaccines, and personalized medicine, the market for bioprocess bags is expected to expand significantly. These bags are used across various stages of biomanufacturing, from cell culture to the final production of therapeutic products. As the demand for high-quality, cost-effective, and scalable solutions increases, bioprocess bags are becoming a vital component in the production of biopharmaceuticals, vaccines, and other biologics, particularly in the rapidly expanding areas of gene therapy and immunotherapy.

Single-Use Bioprocess Bags are the Largest Owing to Cost Efficiency and Flexibility

Single-use bioprocess bags are the largest subsegment in the market, primarily due to their cost efficiency, ease of use, and scalability. These bags are extensively utilized in cell culture, media preparation, and drug production, offering significant advantages over traditional reusable stainless-steel systems. The ability to discard the bags after each use eliminates the need for cleaning, sterilization, and validation procedures, reducing both time and costs.

The growing trend towards disposable, flexible systems in biomanufacturing has fueled the adoption of single-use bioprocess bags. These bags are integral to the production of biopharmaceuticals, vaccines, and gene therapies, where maintaining sterile conditions and avoiding cross-contamination is crucial. As biopharmaceutical production continues to shift towards single-use solutions for their economic and operational benefits, single-use bioprocess bags are expected to remain the dominant subsegment.

Biopharmaceutical Production is the Largest Owing to the Demand for Biologics

Biopharmaceutical production is the largest application in the bioprocess bags market, driven by the increasing demand for biologic drugs and vaccines. The production of biologics—such as monoclonal antibodies, recombinant proteins, and gene therapies—requires highly controlled environments, where bioprocess bags play a critical role in facilitating sterile, scalable, and flexible manufacturing processes. These bags are used for a variety of purposes, including cell culture, filtration, mixing, and storage.

As the biopharmaceutical industry continues to grow, driven by the expanding pipeline of biologics, bioprocess bags are becoming increasingly essential to ensuring the efficient and cost-effective production of these therapeutic products. The shift toward biologic drugs and the increasing complexity of manufacturing processes make biopharmaceutical production the largest and most significant application in the market.

Pharmaceuticals & Biotechnology is the Largest Owing to Expanding Biologic Production

The pharmaceuticals and biotechnology industry is the largest end-user sector for bioprocess bags, owing to the continuous growth in the production of biologics, vaccines, and therapeutic proteins. The demand for high-quality biopharmaceutical products, including monoclonal antibodies and gene therapies, is driving the need for reliable, sterile, and scalable manufacturing solutions, such as bioprocess bags.

Biopharmaceutical companies are increasingly adopting single-use bioprocessing systems to reduce capital expenditures and enhance operational flexibility. As the global demand for biologic therapies and vaccines continues to rise, pharmaceuticals and biotechnology will remain the largest end-user of bioprocess bags, supporting the market's expansion and innovation in manufacturing processes.

North America is Largest Owing to Strong Biopharmaceutical Industry and R&D Focus

North America is the largest region in the bioprocess bags market, due to the region's dominant position in the biopharmaceutical industry and its focus on research and development (R&D). The U.S., in particular, is home to many leading pharmaceutical and biotechnology companies that drive demand for bioprocessing technologies, including bioprocess bags. The region’s advanced healthcare infrastructure, high levels of investment in biopharmaceuticals, and favorable regulatory environment contribute to North America's leadership in the market.

In addition to biopharmaceutical production, the region’s strong R&D efforts in areas such as gene therapy, immunotherapy, and biologic drug development further propel the adoption of single-use systems like bioprocess bags. As the market continues to expand in North America, it is expected to maintain its dominant position due to continuous innovation, industry growth, and regulatory support.

Leading Companies and Competitive Landscape

The bioprocess bags market is highly competitive, with leading players such as Thermo Fisher Scientific, Sartorius AG, Merck KGaA, and Danaher Corporation providing a wide range of products and solutions for biomanufacturing. These companies offer single-use bioprocess bags, multi-layer bags, and bioprocess bag assemblies that cater to the diverse needs of biopharmaceutical, biotechnology, and healthcare industries.

The competitive landscape is characterized by ongoing innovation and strategic collaborations. Companies are focusing on expanding their product portfolios, improving the functionality of bioprocess bags, and addressing specific market needs, such as enhancing the compatibility of bags with various biopharmaceutical production processes. With the growing demand for biologics, personalized medicine, and gene therapies, companies in the bioprocess bags market are investing heavily in research and development to stay ahead of industry trends and maintain their competitive edge.

Recent Developments:

• In January 2025, Thermo Fisher Scientific expanded its single-use bioprocess bags portfolio to address growing demand in vaccine manufacturing.
• In December 2024, Sartorius Stedim Biotech launched a new multi-layer bioprocess bag system aimed at improving production efficiency in biopharmaceuticals.
• In November 2024, Pall Corporation entered a strategic partnership with a leading biopharmaceutical company to develop customized bioprocessing solutions.
• In October 2024, GE Healthcare announced the acquisition of a bioprocess bag manufacturer to strengthen its position in the bioprocessing market.
• In September 2024, Merck KGaA introduced an innovative bioprocess bag assembly solution designed for large-scale protein purification.

List of Leading Companies:

• Thermo Fisher Scientific
• Sartorius Stedim Biotech
• GE Healthcare
• Merck KGaA
• Lonza Group
• Pall Corporation
• Danaher Corporation
• W. L. Gore & Associates
• Saint-Gobain Performance Plastics
• Entegris, Inc.
• Meissner Filtration Products
• Bio-Rad Laboratories
• 3M
• Becton Dickinson and Company
• Kabbage BioTech

Report Scope: